Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâ€™s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

06-23	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI
04-29	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2026	CI

Market Cap	122M 140M 112M 105M 198M 13.3B 201M 1.35B 524M 6.54B 524M 513M 22.53B	P/E 2026 *	-5.02x	P/E 2027 *	-5.2x
Enterprise Value	114M 131M 105M 97.81M 186M 12.44B 188M 1.26B 490M 6.11B 490M 480M 21.06B	EV / Sales 2026 *	9.97x	EV / Sales 2027 *	5.3x
Free-Float	21.17%	Yield 2026 *	-	Yield 2027 *	-

06-23	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI
04-29	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2026	CI
04-17	Heidelberg Pharma AG Announces Chief Financial Officer Changes	CI
04-09	Heidelberg Pharma Sets Dose for Mid-stage Trial of Multiple Myeloma Drug Candidate	MT
04-09	Heidelberg Pharma AG Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101	CI
04-04	Heidelberg Pharma AG Presents Data from Its ADC Technology Platform At AACR Annual Meeting	CI
03-31	Heidelberg Pharma AG, 2025 Earnings Call, Mar 26, 2026
03-26	Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2025	CI
03-26	Heidelberg Pharma AG Provides Earnings Guidance for the Fiscal Year 2026	CI
03-18	Heidelberg Pharma Set to Get Milestone Payment for Plasma Cell Disorders Treatment Clinical Study	MT
03-18	Heidelberg Pharma AG Receives Milestone Payment for Clinical Study with HDP-101 in China	CI
03-06	Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement	RE
11-25	Heidelberg Pharma Names New CEO	MT

06-23	Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026	EQ
05-13	Heidelberg Pharma : Explanations on the resolutionless agenda item 1 (HDP ExplanationItem1)	PU
05-13	Heidelberg Pharma : CV of the proposed Supervisory Board candidate (202605 CV AR 2026 engl)	PU
05-13	Heidelberg Pharma : Articles of Association (20260121 HeidelbergPharma ArticlesAssociation)	PU
05-13	Heidelberg Pharma : Explanation of shareholders' rights (HDP explanations of the rights of shareholders copy 2)	PU

06-23	Heidelberg Pharma : Voting results (HPHA Abstimmung Liste copy 1)
06-23	Heidelberg Pharma : Abstimmungsergebnisse (HPHA Abstimmung Liste)
06-23	Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026
06-19	Kalender der Dividendenausschüttungen und Hauptversammlungen vom 22. bis 26. Juni 2026
05-15	HV: Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Ladenburg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Wilex AG Stock Xetra

Stocks

DE0006614720

Biotechnology & Medical Research

Valuation: Wilex AG

Latest news : Wilex AG

Last Transcript: Wilex AG

Analysts' recommendations: Wilex AG

Press Releases: Wilex AG

News in other languages: Wilex AG

Managers and Directors: Wilex AG

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Dong Zhou Liu CEO	Chief Executive Officer	-	2025-11-23
Peter Willinger DFI	Director of Finance/CFO	-	2026-04-30
András Strassz CTO	Chief Tech/Sci/R&D Officer	-	2021-02-28

Director	Title	Age	Since
Georg F. Baur CHM	Chairman	76	2000-12-13
Birgit Kudlek BRD	Director/Board Member	59	2012-05-24
Mathias Hothum BRD	Director/Board Member	58	2015-07-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+0.68%	+5.92%	+80.45%	+137.78%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.51%	+94.88%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+45.58%	-1.42%	19.69B
GENMAB A/S	-0.29%	+9.78%	+44.62%	-27.94%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+178.93%	+360.74%	16.22B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+42.82%	-	14.84B
Average	+2.87%	+8.57%	+54.64%	+148.04%	27.28B
Weighted average by Cap.	+2.46%	+6.47%	+59.06%	+137.71%

	2026 *	2027 *
Net sales	11.45M 13.1M 10.52M 9.81M 18.6M 1.25B 18.89M 126M 49.11M 613M 49.16M 48.11M 2.11B	19.8M 22.65M 18.2M 16.96M 32.17M 2.16B 32.66M 218M 84.92M 1.06B 85.02M 83.19M 3.65B
Net income	-24.3M -27.8M -22.33M -20.82M -39.48M -2.65B -40.08M -268M -104M -1.3B -104M -102M -4.48B	-23.5M -26.88M -21.6M -20.13M -38.18M -2.56B -38.76M -259M -101M -1.26B -101M -98.74M -4.34B
Net Debt	-7.93M -9.07M -7.29M -6.79M -12.88M -864M -13.08M -87.47M -34M -424M -34.04M -33.31M -1.46B	-17.24M -19.72M -15.84M -14.76M -28M -1.88B -28.43M -190M -73.92M -923M -74M -72.41M -3.18B

End-of-day quote Xetra Other stock markets
- ^EUR	-